Drug Search Results
More Filters [+]

Diphenhydramine

Alternative Names: diphenhydramine, benadryl, Diphenydramine, difenhidramina, diphen, hydramine, belix, silphen, dibenil, beldin, antitussive, vicks formula 44, di-phen, benylin
Latest Update: 2024-05-13
Latest Update Note: News Article

Product Description

Diphenhydramine is used to relieve red, irritated, itchy, watery eyes; sneezing; and runny nose caused by hay fever, allergies, or the common cold. Diphenhydramine is also used to relieve cough caused by minor throat or airway irritation.

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diphenhydramine

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Lithuania, Mexico, New Zealand, Norway, Peru, Poland, Russia, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Acute Urticaria|Glomerulonephritis, Membranous|Kidney Diseases|Lupus Erythematosus, Systemic|Lupus Nephritis|Membranous Nephropathy|Multiple Myeloma|Multiple Sclerosis|Nephrosis, Lipoid|Nephrotic Syndrome|Schizophrenia

Phase 2: Diffuse Large B-Cell Lymphoma

Phase 1: Healthy Volunteers|Insomnia|Pain Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EFC15992

P3

Active, not recruiting

Multiple Myeloma

2030-11-11

25%

EFC15992

P3

Active, not recruiting

Multiple Myeloma

2030-11-11

25%

EFC15992

P3

Active, not recruiting

Multiple Myeloma

2030-11-11

25%

EFC15992

P3

Active, not recruiting

Multiple Myeloma

2030-11-11

25%

EFC15992

P3

Active, not recruiting

Multiple Myeloma

2030-11-11

25%

INShore

P3

Recruiting

Nephrotic Syndrome|Nephrosis, Lipoid

2026-08-15

47%

MAJESTY

P3

Active, not recruiting

Glomerulonephritis, Membranous|Kidney Diseases|Membranous Nephropathy

2025-12-29

76%

ALLEGORY

P3

Recruiting

Lupus Erythematosus, Systemic

2025-11-30

86%

Recent News Events